Yap methylation‐induced FGL1 expression suppresses anti‐tumor immunity and promotes tumor progression in <i>KRAS</i> ‐driven lung adenocarcinoma
FGL1 could be used as a diagnostic biomarker of KRAS-mutated lung cancer, and targeting the Yap-FGL1 axis could increase the efficacy of anti-PD-1 immunotherapy.
Authors
- Sainan Miao (ORCID: https://orcid.org/0009-0003-9219-7225)
- Huan Qiu (ORCID: https://orcid.org/0009-0002-6457-8891)
- Ningjie Zhang
- Mengqi Chai (ORCID: https://orcid.org/0000-0002-6363-0216)
- Weihua Zhu (ORCID: https://orcid.org/0000-0002-0295-8744)
- Pengfei Ye (ORCID: https://orcid.org/0000-0001-6415-1471)
- Zijie Gao (ORCID: https://orcid.org/0009-0002-8974-5633)
- Wei Wei
- Siqi Li (ORCID: https://orcid.org/0000-0003-0666-7423)
- Mei Yang (ORCID: https://orcid.org/0000-0002-4233-7889)
- Shihao Zhang (ORCID: https://orcid.org/0000-0002-5781-2080)
- Yue An
- Shijie Guo
- Manman Yu
- Ning-Ning Sun
- Jiang Ji (ORCID: https://orcid.org/0000-0002-0541-4531)
- Jingjing Yu
- Hui Zhang (ORCID: https://orcid.org/0009-0005-3796-0384)
- Wenmin Liu
- Cuncun Zhang
- Yuru Ji
- Jian Hong
Institutions
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Ministry of Education (KN)
Publication Details
- Journal
- Cancer Communications
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1002/cac2.12609
- Citations
- 11
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 3.59